Formycon And Alvotech Offer Updates On Aflibercept
Eylea Biosimilars Jostle For Position, With A Filing Acceptance And Trial Results
Biosimilar aflibercept rivals to Eylea are advancing towards approval, with Formycon reporting EMA acceptance of its filing for its FYB203 version and Alvotech disclosing positive trial results for its AVT06 candidate.
